Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17(11):671–84.
McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P. collaborators ESEs: therapy of aggressive pituitary tumours and carcinomas: outcomes of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–76.
Zhang J, Gu J, Ma Y, Huang Y, Wang J, Wu Z, Zhong Q, Wang S. Uneven distribution of regional blood provide prompts the cystic change of pituitary adenoma. World Neurosurg. 2017;103:37–44.
Xiao D, Wang S, Zhao L, Zhong Q, Huang Y, Ding C. Fluid-fluid degree on magnetic resonance photos could predict the prevalence of pituitary adenomas in cystic sellar-suprasellar lots. Exp Ther Med. 2017;13(6):3123–9.
Shepard MJ, Snyder MH, Soldozy S, Ampie LL, Morales-Valero SF, Jane JA. Radiological and medical outcomes of pituitary apoplexy: comparability of conservative administration versus early surgical intervention. J Neurosurg. 2021;135(5):1310-8.
Marx C, Rabilloud M, Borson Chazot F, Tilikete C, Jouanneau E, Raverot G. A key function for conservative therapy within the administration of pituitary apoplexy. Endocrine. 2021;71(1):168–77.
Dallapiazza R, Bond AE, Grober Y, Louis RG, Payne SC, Oldfield EH, Jane JA Jr. Retrospective evaluation of a concurrent sequence of microscopic versus endoscopic transsphenoidal surgical procedures for Knosp Grades 0–2 nonfunctioning pituitary macroadenomas at a single establishment. J Neurosurg. 2014;121(3):511–7.
Mooney MA, Hardesty DA, Sheehy JP, Hen R, Chapple Okay, White WL, Little AS. Interrater and intrarater reliability of the Knosp scale for pituitary adenoma grading. J Neurosurg. 2017;126(5):1714–9.
Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D’Avella D, et al. Temozolomide and pasireotide therapy for aggressive pituitary adenoma: experience at a tertiary care heart. J Neurooncol. 2015;122(1):189–96.
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Dekkers O, Popovic V, Wierinckx A, McCormack A, Petersenn S, Burman P, Raverot G, et al. Are aggressive pituitary tumors and carcinomas two sides of the identical coin? Pathologists reply to clinician’s questions. Rev Endocr Metab Disord. 2020;21(2):243–51.
Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers within the oncogenic Okay-RAS/Ki67/HIF-1alpha pathway to foretell survival in resectable pancreatic most cancers. Br J Most cancers. 2015;112(3):514–22.
Chesney Okay, Memel Z, Pangal DJ, Donoho D, Hurth Okay, Mathew A, Carmichael JD, Zada G. Variability and lack of prognostic worth related to atypical pituitary adenoma analysis: a scientific overview and important evaluation of the diagnostic standards. Neurosurgery. 2018;83(4):602–10.
Hsu CY, Guo WY, Chien CP, Ho DM. MIB-1 labeling index correlated with magnetic resonance imaging detected tumor quantity doubling time in pituitary adenoma. Eur J Endocrinol. 2010;162(6):1027–33.
Ugga L, Cuocolo R, Solari D, Guadagno E, D’Amico A, Somma T, Cappabianca P, Del Del Basso de Caro ML, Cavallo LM, Brunetti A. Prediction of excessive proliferative index in pituitary macroadenomas utilizing MRI-based radiomics and machine studying. Neuroradiology. 2019;61(12):1365–73.
Knosp E, Steiner E, Kitz Okay, Matula C. Pituitary adenomas with invasion of the cavernous sinus house: a magnetic resonance imaging classification in contrast with surgical findings. Neurosurgery. 1993;33(4):610–7. Dialogue 617–618.
Hsi ED. A sensible strategy for evaluating new antibodies within the medical immunohistochemistry laboratory. Arch Pathol Lab Med. 2001;125(2):289–94.
Kontogeorgos G. Improvements and controversies within the WHO classification of pituitary adenomas. Acta Neuropathol. 2006;111(1):73–5.
Zahir ST, Shateri S, Yazdi MB, Barand P, Zare Z. Evaluating the detection of lymph nodes micrometastasis in breast most cancers by the hematoxylin and eosin staining technique (H&E) and the immunohistochemical technique (IHC). Int J Most cancers Manag. 2017;10:e11743.
Mei T, Zhang J, Wei L, Qi X, Ma Y, Liu X, Chen S, Li S, Wu J, Wang S. GLUT3 expression in cystic change induced by hypoxia in pituitary adenomas. Endocr Join. 2018;7(12):1518–27.
Monsalves E, Larjani S, Loyola Godoy B, Juraschka Okay, Carvalho F, Kucharczyk W, Kulkarni A, Mete O, Gentili F, Ezzat S, et al. Progress patterns of pituitary adenomas and histopathological correlates. J Clin Endocrinol Metab. 2014;99(4):1330–8.
Grimm F, Maurus R, Beschorner R, Naros G, Stanojevic M, Gugel I, Giese S, Bier G, Bender B, Honegger J. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor measurement in useful and nonfunctional pituitary adenomas. Acta Neurochir. 2019;161(6):1149–56.
Kim JK, Kim HD, Jun MJ, Yun SC, Shim JH, Lee HC, Lee D, An J, Lim YS, Chung YH, et al. Tumor quantity doubling time as a dynamic prognostic marker for sufferers with hepatocellular carcinoma. Dig Dis Sci. 2017;62(10):2923–31.
Zhao M, Deng J, She Y, Chen C. Prognostic impression of solid-part tumour quantity doubling time: is it nonetheless priceless within the subgroup of sufferers with part-solid nodules? Eur J Cardiothorac Surg. 2020;57(5):1013.
Çalapkulu M, Sencar ME, Unsal IO, Sakiz D, Duger H, Özbek M, Çakal E. Tumor quantity can be utilized as a parameter indicating the severity of illness in parathyroid most cancers. Endocr Pract. 2021;27(7):706–9.
Joseph LL, Boddu D, Srinivasan HN, Regi SS, Antonisamy B, John R, Mathew LG, Totadri S. Postchemotherapy tumor quantity as a prognostic indicator in Wilms tumor: a single-center expertise from South India. Pediatr Blood Most cancers. 2022;69(2):e29454.
Almeida JP, Sanchez MM, Karekezi C, Warsi N, Fernández-Gajardo R, Panwar J, Mansouri A, Suppiah S, Nassiri F, Nejad R, et al. Pituitary apoplexy: outcomes of surgical and conservative administration medical sequence and overview of the literature. World neurosurgery. 2019;130:e988–99.
Cavalli A, Martin A, Connolly DJ, Mirza S, Sinha S. Pituitary apoplexy: tips on how to outline secure boundaries of conservative administration? Early and long-term outcomes from a single UK tertiary neurosurgical unit. Br J Neurosurg. 2021;35(3):334–40.
Oge DD, Arsava EM, Pektezel MY, Gocmen R, Topcuoglu MA. Intracerebral hemorrhage quantity estimation: Is modification of the ABC/2 method crucial based on the hematoma form? Clin Neurol Neurosurg. 2021;207:106779.
Zhao B, Jia WB, Zhang LY, Wang TZ. 1/2SH: a easy, correct, and dependable technique of calculating the hematoma quantity of spontaneous intracerebral hemorrhage. Stroke. 2020;51(1):193–201.
Sharifi G, Sabahi M, Amin A, Dilmaghani NA, Nejad AM, Davoudi Z, Mohajeri-Tehrani M, Rezaei O, Borghei-Razavi H. Patterns of extrasellar invasive progress of pituitary adenomas with regular sellar cavity measurement. Clin Neurol Neurosurg. 2021;209:106942.
Berkmann S, Lattmann J, Schuetz P, Diepers M, Remonda L, Fandino J, Buchfelder M, Mueller B. The Form grading system: a classification for progress patterns of pituitary adenomas. Acta Neurochir. 2021;163(11):3181–9.
Ringstad GA, Emblem KE, Holland D, Dale AM, Bjornerud A, Hald JK. Evaluation of pituitary adenoma volumetric change utilizing longitudinal MR picture registration. Neuroradiology. 2012;54(5):435–43.
Wang J, Huang Z, Wang F, Yu X, Li D. Materialise’s interactive medical picture management system (MIMICS) is possible for volumetric measurement of urinary calculus. Urolithiasis. 2020;48(5):443–6.
Yokoyama S, Hirano H, Moroki Okay, Goto M, Imamura S, Kuratsu JI. Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery. 2001;49(4):857–62. Dialogue 862–853.
Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, et al. A brand new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control examine of 410 sufferers with 8 years post-operative follow-up. Acta Neuropathol. 2013;126(1):123–35.
Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with progress velocity and invasiveness. J Neurosurg. 2003;99(4):674–9.
Popescu MN, Ionescu E, Iovanescu LC, Cotoi BV, Popescu AI, Ganescu AE, Glodeanu A, Geormaneanu C, Moraru A, Patrascu A. Scientific aggression of prolactinomas: correlations with invasion and recurrence. Rom J Morphol Embryol. 2013;54(4):1075–80.
Lopes MBS. The 2017 World Well being Group classification of tumors of the pituitary gland: a abstract. Acta Neuropathol. 2017;134(4):521–35.
